{
    "medicine_id": "aecfab88af382821fa08ae20c276a54d2fb187a4",
    "platform_id": "DB11761",
    "metadata": {
        "name": "Ibsrela 50 mg Tablet",
        "composition": "50 mg Tenapanor",
        "clinical_particulars": {
            "therapeutic_indications": "Tenapanor is indicated for the treatment of constipation predominant irritable bowel syndrome IBS C in adults L8558 It is also currently being investigated as a treatment for hyperphosphatemia in chronic kidney disease patients undergoing dialysis NCT02081534 and NCT02675998 A185489",
            "contraindications": {
                "disease": "Symptoms of overdose are likely to be consistent with tenapanor s adverse effect profile and may therefore include gastrointestinal effects such as diarrhea Dehydration may occur depending on duration and severity of diarrhea L8558 No specific management strategies have been proposed in cases of overdose",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Through the inhibition of dietary sodium absorption tenapanor causes an increase in water secretion into the intestines thereby decreasing transit time and softening stool consistency L8558",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}